According to today’s article on Bloomberg Quint, “EU Could Approve BioNTech, Moderna Vaccines in December.”
Shares of Moderna rose 4.78% to $97.2 at 10:48 EST on Friday. The Nasdaq Stock Market is rising 0.06% to $11911.7, on what seems, so far, a somewhat positive trend trading session on The Nasdaq Stock Market.
According to yesterday’s article on Bloomberg Quint, “Moderna Vaccine Production Is Gearing Up, Partner Lonza Says.”
Moderna’s last close was $92.77, below its 52-week high of $103.2.
Moderna’s sales growth is 1216.8% for the ongoing quarter and 2299% for the next. The company’s growth estimates for the current quarter is a negative 67.6% and positive 142.9% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s stock is valued at $97.2 at 10:48 EST, under its 52-week high of $103.2 and way higher than its 52-week low of $17.68.
Moderna’s worth is way above its 50-day moving average of $75.37 and way above its 200-day moving average of $68.93.
Moderna vaccine found highly effective at preventing covid. According to Bloomberg Quint on Mon Nov 16, “Moderna shares rised more than 9% in pre-market U.S.”
According to Bloomberg Quint on Tue Nov 17, “Moderna Vaccine Offers Possible Antidote to Deep-Freeze Problem.”